Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. - Wikidata - wikimedia - TriplyDB

Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.

Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.

http://www.wikidata.org/entity/Q40271507

about

Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis Recent advances in understanding and managing cholestasis Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer FXR signaling in the enterohepatic system Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis Bile acid nuclear receptor FXR and digestive system diseases Bile acid signaling in metabolic disease and drug therapy Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo FXR regulates liver repair after CCl4-induced toxic injury Farnesoid X Receptor an Emerging Target to Combat Obesity.Exposure to the synthetic FXR agonist GW4064 causes alterations in gene expression and sublethal hepatotoxicity in eleutheroembryo medaka (Oryzias latipes)Farnesoid X receptor protects liver cells from apoptosis induced by serum deprivation in vitro and fasting in vivo.Activation of Sirt1/FXR Signaling Pathway Attenuates Triptolide-Induced Hepatotoxicity in Rats.Clinical application of transcriptional activators of bile salt transporters.Nuclear receptors: mediators and modifiers of inflammation-induced cholestasis.Two farnesoid X receptor alpha isoforms in Japanese medaka (Oryzias latipes) are differentially activated in vitro.Targets for current pharmacologic therapy in cholesterol gallstone disease.Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity.Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.Impairment of bilirubin clearance and intestinal interleukin-6 expression in bile duct-ligated vitamin D receptor null mice Endocrine functions of bile acids.Deciphering the nuclear bile acid receptor FXR paradigm.Resveratrol effectively attenuates α-naphthyl-isothiocyanate-induced acute cholestasis and liver injury through choleretic and anti-inflammatory mechanisms.Tissue-specific function of farnesoid X receptor in liver and intestine Benefit of farnesoid X receptor inhibition in obstructive cholestasis.Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3.Swertianlarin, isolated from Swertia mussotii Franch, increases detoxification enzymes and efflux transporters expression in rats.Chronic activation of FXR in transgenic mice caused perinatal toxicity and sensitized mice to cholesterol toxicity.Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma.New perspectives for the treatment of cholestasis: lessons from basic science applied clinically.Farnesoid X Receptor Agonist Represses Cytochrome P450 2D6 Expression by Upregulating Small Heterodimer Partner.Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice.Swertianlarin, an Herbal Agent Derived from Swertia mussotii Franch, Attenuates Liver Injury, Inflammation, and Cholestasis in Common Bile Duct-Ligated Rats The enterohepatic nuclear receptors are major regulators of the enterohepatic circulation of bile salts.Therapy of gallstone disease: What it was, what it is, what it will be Organic anion transporting polypeptide 1a1 null mice are sensitive to cholestatic liver injury Bile acids via FXR initiate the expression of major transporters involved in the enterohepatic circulation of bile acids in newborn mice.Intravenous Lipid Emulsions in Parenteral Nutrition FXR and liver carcinogenesis Novel insight into mechanisms of cholestatic liver injury.

P2860

Q24564745-C3E9CE7E-7C1F-41AF-9D48-5FFEC21000A3 Q26748537-E92B50C3-DDE6-49E1-AA9C-3E20C6349DF0 Q26800206-EA2C2105-371F-49FF-A123-589FA2FC41AA Q27014753-8E7C6F8C-1E6E-4B85-BEE1-DA20A4986F13 Q27309876-C7380B00-D46E-46CC-BCF8-4482658B093A Q28085493-D70C1BFB-D9FA-476C-8A15-A643DA203214 Q28244875-BBB94068-C4D2-4DAF-8183-2FE8A6330718 Q28296042-9675059F-4A21-496D-83B5-FC488AF4FAB0 Q28396872-BD717421-6A37-44AF-9465-DB582208829F Q30235507-29BBB20B-6A11-4511-9AA1-C5A5FD207DFE Q30494047-544FB345-E983-4322-8CED-F8DD1BFE6E51 Q33642712-48D7E445-F77B-4A8E-931F-66E014874A1D Q33650563-51E72480-64A8-41C2-9DF0-6A9A598850FC Q33709930-76091517-ECC0-4DC9-9E6D-6E47B7ABF6F3 Q33859400-588CC1A5-4F2A-43A9-87D9-0C5AADE896BE Q33869488-833E3DF3-175C-4960-877C-CA18FACB8200 Q34041538-7D892985-CCF7-440C-A243-91AF35E332DE Q34132197-02C83DC8-1E55-48AC-8D27-42C91C51D7F6 Q34386625-09BFC56D-C360-48CF-8112-0E65B99EBC7F Q34512542-695F83A7-3569-437B-854B-401717A74154 Q34545426-7AF3426E-E36C-4252-9B06-BED709E9B261 Q34626518-298DF1C5-D14F-49FC-B04F-19ABA7CE1176 Q34664507-0564FA31-E846-436C-A881-676C340150FD Q34714107-2392AB2D-6DAC-4F89-9D5A-147A9B917CF1 Q34983994-CA864D50-EEFE-4AA5-A446-D69C56A5AE55 Q35054998-37D170D2-3D1F-41D3-8BA0-648AFE638CA1 Q35145151-8A484882-28CD-4A4F-BA4A-38934EA637B1 Q35441714-627D69E8-9387-4C33-A11F-57F00786F7E2 Q35633633-B1A1A9AE-71FD-48C2-AD8F-906D8C02D1C1 Q35741546-1C04603E-576C-49B0-979E-7EED45728061 Q35745253-7A29FFAE-2B80-4CC1-A4C2-CB6E3281975C Q35765708-C841F7B5-F706-413C-AA99-2B98D0D4A084 Q35932294-59E4F7BE-8D07-4753-B4E5-BF1F55222EEC Q35932368-0FB67EEE-C739-40C6-8627-19FDBA2FE1AE Q35948819-DD1340F2-9ACE-47C4-8815-41A812A57180 Q35969305-D78992A1-FCE3-4AFC-9A63-8635AF7C79F0 Q35994016-A3E84A40-5923-470A-9DEB-8EE94E3917F6 Q36033721-4B7CCFB4-37B2-4161-B009-019067576D39 Q36063712-071799DA-ECEC-45A9-9DAB-DE826CE3F27B Q36285749-7B4F714D-3368-49A6-B64C-94B0A133051F

P2860

Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.

http://www.wikidata.org/entity/Q40271507

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Hepatoprotection by the farnes ...... and extrahepatic cholestasis.

@en

type

label

Hepatoprotection by the farnes ...... and extrahepatic cholestasis.

@en

prefLabel

Hepatoprotection by the farnes ...... and extrahepatic cholestasis.

@en

P1433

Q40271507-7425C9C3-55EE-4112-A701-5FA568618513

P1476

Q40271507-E0160FD5-F80E-49ED-A17E-3227EDFB0F03

P2093

Q40271507-1674C5C5-F8F1-4D74-AFC4-DCBC9571B2EA

Q40271507-2115F7AA-6C24-475A-8CFF-F5459CE3A04B

Q40271507-480FDB29-0C71-46B8-B2B4-ACF2644FC351

Q40271507-502454F4-328B-45D8-BAE6-AD58AC645F61

Q40271507-585DC272-E360-492A-8B5E-77C3476341F4

Q40271507-5D3B0951-AEE0-4D56-9BB0-DC697673D6C3

Q40271507-8A849D84-5C80-4055-9210-00215643AEC5

Q40271507-A02B6EF9-842C-4765-9F9B-04A18425AF9D

Q40271507-A2F0BBF6-6C1C-4B6F-8B33-8F1022BB0C10

Q40271507-DADAD8CB-0151-4AF1-9DA7-EA54DA0C2E2B

P2860

Q40271507-0CA2CAAB-1DF0-4A67-9125-A59D62121B48

Q40271507-0CEBA8EF-D006-4218-84F3-092EF2E3A675

Q40271507-0EF22BD5-1947-427C-9E1E-026555797E6A

Q40271507-0F06DA55-541C-4E61-8F3A-AD2C38943685

Q40271507-0FA301A6-046D-48EF-A688-4AF3555D7505

Q40271507-221CBD91-49B8-4AAA-B3C0-752A8135D778

Q40271507-372643C8-2AC5-4363-998F-F35600AF9F60

Q40271507-3FF77EDE-EAFA-4E4D-B46D-21D01611D347

Q40271507-51DAC8CF-2D21-42C9-8250-4DE98888E97E

Q40271507-563AD23F-8FF2-4CDE-BAA5-4CC99DF3CBF2

P304

Q40271507-13865591-1BC0-478C-B149-8E5C5A7EC593

P31

Q40271507-4DA20237-1A57-4DE2-82CE-3C3BC31C6F3A

P356

Q40271507-5590B799-CC05-42B7-875F-7FD56A4E4687

P407

Q40271507-4FB20A78-5F39-4926-B249-2236FECA76D9

P433

Q40271507-FC942F29-9E94-4256-AB79-B50F8DB2A95F

P478

Q40271507-10868BFE-FFED-4728-BE72-4F65E0AFDC63

P577

Q40271507-3536972E-C6AE-4AEE-BB08-A45A4E9C087D

P698

Q40271507-7EF84B15-ADD2-4DEE-95F4-03B287B19278

P932

Q40271507-797B7C1C-1808-4201-9C90-EA0507D826D2

P356

P1433

Journal of Clinical Investigation

P1476

Hepatoprotection by the farnes ...... and extrahepatic cholestasis.

@en

P2093

Bhasha Desai

http://www.w3.org/2001/XMLSchema#string

Bryan Goodwin

http://www.w3.org/2001/XMLSchema#string

Guizhen Luo

http://www.w3.org/2001/XMLSchema#string

Jane Binz

http://www.w3.org/2001/XMLSchema#string

Kathleen I MacKenzie

http://www.w3.org/2001/XMLSchema#string

Mary Jo Numerick

http://www.w3.org/2001/XMLSchema#string

Stacey A Jones

http://www.w3.org/2001/XMLSchema#string

Steve Dennis

http://www.w3.org/2001/XMLSchema#string

Steven A Kliewer

http://www.w3.org/2001/XMLSchema#string

Traci A Mansfield

http://www.w3.org/2001/XMLSchema#string

P2860

A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis

Identification of a nuclear receptor for bile acids

Bile acids: natural ligands for an orphan nuclear receptor

Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors

Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease

Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis

Hepatic stellate cells: a target for the treatment of liver fibrosis

Endogenous bile acids are ligands for the nuclear receptor FXR/BAR

A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome

A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis

P304

1678-1687

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI18945

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P577

2003-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14623915

http://www.w3.org/2001/XMLSchema#string

P932

281645

http://www.w3.org/2001/XMLSchema#string